Source Count: 15 | Weighted Score: 40 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: RNA splicing, spliceosome, alternative splicing, exon, intron, pre-mRNA, snRNP, exon skipping, splicing disease, splice site
Category Tags: molecular-biology, RNA, gene-expression, transcription, disease
Cross-References: Z_4_14 — RNA · Z_5_08 — DNA · Z_1_15 — Long Non-Coding RNA

QUICK SUMMARY

RNA splicing — the process by which intervening sequences (introns) are removed from precursor messenger RNA (pre-mRNA) and the remaining sequences (exons) are joined together to form the mature mRNA — is a fundamental step in eukaryotic gene expression and a source of extraordinary proteomic diversity through alternative splicing. In the human genome, ~95% of multi-exon genes undergo alternative splicing, generating on average ~7 mRNA isoforms per gene and enabling ~20,000 protein-coding genes to produce an estimated >100,000 distinct protein variants. The splicing reaction is catalyzed by the spliceosome — a massive (~3 MDa) ribonucleoprotein machine composed of five small nuclear RNAs (snRNAs: U1, U2, U4, U5, U6) and ~150 associated proteins, assembling de novo on each intron in an ordered sequence of RNA-RNA, RNA-protein, and protein-protein interactions. The spliceosome recognizes conserved sequence elements at the 5' splice site (GU dinucleotide), the 3' splice site (AG dinucleotide), the branch point (an adenosine ~20–50 nt upstream of the 3' splice site), and the polypyrimidine tract. Two transesterification reactions excise the intron as a lariat structure and ligate the flanking exons. Alternative splicing — the regulated inclusion or exclusion of specific exons, retention of introns, or use of alternative splice sites — is controlled by cis-regulatory elements (exonic/intronic splicing enhancers and silencers) and trans-acting splicing factors (SR proteins, hnRNPs). Mutations that disrupt splicing account for an estimated ~15–50% of all disease-causing mutations in humans, producing aberrant mRNA isoforms through exon skipping, intron retention, or activation of cryptic splice sites; notable examples include spinal muscular atrophy (SMA), β-thalassemia, and certain cancers. Splicing-targeted therapies — antisense oligonucleotides (nusinersen/Spinraza for SMA) that redirect splicing patterns — represent a transformative class of precision medicines.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Discovery and Mechanism

• Discovery: introns and RNA splicing were discovered independently by Phillip Sharp and Richard Roberts (1977, Nobel Prize 1993) in studies of adenovirus mRNA; they found that mature mRNA was shorter than its genomic template, with intervening sequences removed during processing
• Spliceosome assembly: the five snRNPs (U1, U2, U4/U6, U5) assemble on pre-mRNA in a defined order: U1 snRNP recognizes the 5' splice site → U2 snRNP binds the branch point → the U4/U6·U5 tri-snRNP joins → extensive rearrangements form the catalytically active spliceosome → two transesterification reactions: (i) the 2'-OH of the branch point adenosine attacks the 5' splice site, cleaving the exon-intron junction and forming a lariat intermediate; (ii) the 3'-OH of the free upstream exon attacks the 3' splice site, joining the exons and releasing the lariat intron
• Catalytic center: the spliceosome is a ribozyme — the catalytic core is formed by RNA (U2 and U6 snRNAs) rather than protein, similar to self-splicing group II introns, suggesting an ancient evolutionary origin

1.2 Alternative Splicing

• Types of alternative splicing: (1) exon skipping/inclusion (most common in mammals — ~40% of alternative splicing events); (2) alternative 5' splice site selection; (3) alternative 3' splice site selection; (4) intron retention (most common in plants; less common but increasingly recognized in mammals); (5) mutually exclusive exons
• Regulatory elements: cis-acting sequences include exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs), and intronic splicing silencers (ISSs); trans-acting factors include SR proteins (SRSF1, SRSF2 — generally promote exon inclusion by binding ESEs) and hnRNPs (hnRNP A1, hnRNP I/PTB — generally promote exon skipping by binding silencers)
• Tissue-specific splicing: alternative splicing patterns differ dramatically between tissues (e.g., the DSCAM gene in Drosophila can generate >38,000 isoforms through combinatorial alternative splicing — the most extreme case known); tissue-specific splicing factors (e.g., NOVA in neurons, MBNL in muscle, ESRP in epithelium) direct tissue-appropriate isoform selection

1.3 Splicing and Disease

• ~15–50% of human disease-causing mutations affect RNA splicing — including mutations at canonical splice sites (GT/AG dinucleotides), branch point mutations, and mutations in exonic or intronic splicing regulatory elements that alter splicing factor binding
• Spinal Muscular Atrophy (SMA): caused by loss-of-function mutations in the SMN1 gene; the near-identical SMN2 gene differs by a single nucleotide (C→T in exon 7) that converts an ESE to an ESS, causing exon 7 skipping in ~90% of SMN2 transcripts → producing a truncated, unstable SMN protein; nusinersen (Spinraza) — an antisense oligonucleotide that binds an intronic splicing silencer in SMN2 pre-mRNA — forces exon 7 inclusion, restoring full-length SMN protein production; FDA-approved 2016

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Splicing Kinetics and Co-transcriptional Splicing

• Splicing occurs co-transcriptionally — while RNA polymerase II is still transcribing the gene — and splice site recognition is influenced by transcription speed (RNA pol II elongation rate), chromatin structure (histone modifications near exons correlate with splicing outcomes), and the physical coupling between transcription and splicing machineries; the "kinetic model" proposes that slow RNA pol II elongation favors inclusion of weak exons by allowing more time for splice site recognition

2.2 Minor Spliceosome

• The minor (U_4_06-dependent) spliceosome — composed of U_4_05, U_4_06, U4atac, U6atac, and U5 snRNPs — processes a rare class of introns (~0.4% of human introns) with distinct AT-AC (or other non-canonical) splice site sequences; mutations in minor spliceosome components cause diseases including microcephalic osteodysplastic primordial dwarfism (MOPD) and Taybi-Linder syndrome

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Splicing Complexity as a Driver of Organismal Complexity

• The hypothesis that the dramatic increase in alternative splicing complexity in vertebrates (compared to invertebrates and single-celled eukaryotes) contributed significantly to the evolution of organismal complexity — constituting a "splicing code" that expanded the functional proteome without proportionally increasing gene number — is consistent with available data but remains difficult to test rigorously

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Introns Are Purely "Junk"

• [OUTDATED] The early characterization of introns as useless genomic "junk" — introns contain important regulatory elements (enhancers, silencers, snoRNA genes, miRNA genes), influence gene expression levels (intron-mediated enhancement), provide raw material for exon shuffling and gene evolution, and harbor the regulatory sequences that control alternative splicing

COUNTER-ARGUMENTS & CRITICISMS

1. Most Detected Alternative Splicing Events May Be Non-Functional ‘Noise’

Melamud and Moult (2009, "Stochastic Noise in Splicing Machinery," Nucleic Acids Research 37(14): 4873–4886, DOI: 10.1093/nar/gkp471) estimated that a large fraction of alternative transcripts detected by RNA-seq represent stochastic mis-splicing rather than functionally regulated isoforms. Many low-abundance alternative transcripts are rapidly degraded by nonsense-mediated decay, suggesting they are errors rather than regulated outputs.

2. The ‘Splicing Code’ Remains Unpredictive

Barash et al. (2010, "Deciphering the Splicing Code," Nature 465: 53–59, DOI: 10.1038/nature09000) acknowledged that despite thousands of known cis-regulatory elements and trans-acting factors, accurately predicting splicing outcomes from sequence alone remains unreliable. The combinatorial complexity of splicing regulation exceeds current computational models.

3. Therapeutic Splicing Modulation Has Narrow Applicability

Finkel et al. (2017, "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy," New England Journal of Medicine 377(18): 1723–1732, DOI: 10.1056/NEJMoa1702752) reported the success of nusinersen (Spinraza) for SMA, but critics note that this represents an unusually favorable case — a single-gene disease with a well-characterized splicing target. Extending antisense oligonucleotide approaches to complex diseases with polygenic splicing dysregulation faces fundamental challenges.

4. Cryo-EM Spliceosome Structures Capture Snapshots, Not Dynamics

Shi (2017, "Mechanistic Insights into Precursor Messenger RNA Splicing," Nature Reviews Molecular Cell Biology 18(11): 655–670, DOI: 10.1038/nrm.2017.86) noted that while cryo-EM structures have revolutionized spliceosome visualization, they capture static snapshots of particular conformational states. The dynamic rearrangements that drive catalysis occur on timescales and involve intermediate states that current structural methods cannot resolve.

5. Intron-Centric Views May Overstate Splicing’s Evolutionary Importance

Roy and Gilbert (2006, "The Evolution of Spliceosomal Introns: Patterns, Puzzles and Progress," Nature Reviews Genetics 7(3): 211–221, DOI: 10.1038/nrg1807) pointed out that while introns enable alternative splicing, many organisms (including many fungi and some metazoans) have few introns yet comparable proteome complexity. This suggests that alternative splicing, while important, is not the primary mechanism for generating biological complexity.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Sharp, Phillip A. . )90130-9 | 1994 | "Split Genes and RNA Splicing" | Cell | ∅ | 77.6::805–815 | ∅ | ∅ | doi:10.1016/0092-8674(94 | ∅ | ∅ | ∅
2. Wahl, Markus C., Cindy L | 2009 | "The Spliceosome: Design Principles of a Dynamic RNP Machine" | Cell | ∅ | 136.4::701–718 | Will, and Reinhard Lührmann | ∅ | doi:10.1016/j.cell.2009.02.009 | ∅ | ∅ | ∅
3. Wang, Eric T., et al | 2008 | "Alternative Isoform Regulation in Human Tissue Transcriptomes" | Nature | ∅ | 456::470–476 | ∅ | ∅ | doi:10.1038/nature07509 | ∅ | ∅ | ∅
4. Singh, Ravindra N.; Natalia N | 2018 | "Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes" | Advances in Neurobiology | ∅ | 20::31–61 | Singh | ∅ | doi:10.1007/978-3-319-89689-2_2 | ∅ | ∅ | ∅
5. Scotti, Marina M.; Maurice S | 2016 | "RNA Mis-Splicing in Disease" | Nature Reviews Genetics | ∅ | 17.1::19–32 | Swanson | ∅ | doi:10.1038/nrg.2015.3 | ∅ | ∅ | ∅
6. Hua, Yimin, et al | 2010 | "Antisense Correction of SMN2 Splicing in the CNS Rescues Necrosis in a Type III SMA Mouse Model" | Genes & Development | ∅ | 24.15::1634–1644 | ∅ | ∅ | doi:10.1101/gad.1941310 | ∅ | ∅ | ∅
7. Yan, Chuangye, et al | 2015 | "Structure of a Yeast Spliceosome at 3.6-Angstrom Resolution" | Science | ∅ | 349.6253::1182–1191 | ∅ | ∅ | doi:10.1126/science.aac7629 | ∅ | ∅ | ∅
8. Baralle, Francisco E.; Jimena Giudice | 2017 | "Alternative Splicing as a Regulator of Development and Tissue Identity" | Nature Reviews Molecular Cell Biology | ∅ | 18.7::437–451 | ∅ | ∅ | doi:10.1038/nrm.2017.27 | ∅ | ∅ | ∅
9. Melamud, Eugene; John Moult | 2009 | "Stochastic Noise in Splicing Machinery" | Nucleic Acids Research | ∅ | 37.14::4873–4886 | ∅ | ∅ | doi:10.1093/nar/gkp471 | ∅ | ∅ | ∅
10. Barash, Yoseph, et al | 2010 | "Deciphering the Splicing Code" | Nature | ∅ | 465::53–59 | ∅ | ∅ | doi:10.1038/nature09000 | ∅ | ∅ | ∅
11. Finkel, Richard S., et al | 2017 | "Nusinersen versus Sham Control in Infantile-Onset SMA" | New England Journal of Medicine | ∅ | 377.18::1723–1732 | ∅ | ∅ | doi:10.1056/NEJMoa1702752 | ∅ | ∅ | ∅
12. Shi, Yigong | 2017 | "Mechanistic Insights into Precursor Messenger RNA Splicing" | Nature Reviews Molecular Cell Biology | ∅ | 18.11::655–670 | ∅ | ∅ | doi:10.1038/nrm.2017.86 | ∅ | ∅ | ∅
13. Roy, Scott William; Walter Gilbert | 2006 | "The Evolution of Spliceosomal Introns" | Nature Reviews Genetics | ∅ | 7.3::211–221 | ∅ | ∅ | doi:10.1038/nrg1807 | ∅ | ∅ | ∅
14. Nilsen, Timothy W.; Brenton R | 2010 | "Expansion of the Eukaryotic Proteome by Alternative Splicing" | Nature | ∅ | 463::457–463 | Graveley | ∅ | doi:10.1038/nature08909 | ∅ | ∅ | ∅
15. Lee, Yeon; Donald C | 2015 | "Mechanisms and Regulation of Alternative Pre-mRNA Splicing" | Annual Review of Biochemistry | ∅ | 84::291–323 | Rio | ∅ | doi:10.1146/annurev-biochem-060614-034316 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

<table border="1" cellpadding="12" cellspacing="0" style="border-collapse: collapse; border: 2px solid #888; margin-top: 2em; background: #fafafa;">

<tr><td>

⚠️ AI-Assisted Research Disclaimer

This document was generated and structured with the assistance of AI tools.

While every effort is made to ensure accuracy, AI-assisted content may

contain errors, misattributions, or unintended inaccuracies. **Always

verify claims, dates, and sources independently** before citing or relying

on any information presented here.

• Sources may contain errors. Bibliography entries and cross-references

are checked by automated systems, but mistakes can occur. If something

looks wrong, it may be.

• Speculative and unverified claims are clearly labeled. This project

uses a four-tier evidence system:

• Tier 1 — Verified: Peer-reviewed, established scientific consensus.
• Tier 2 — Credible: Academically supported, debated but grounded.
• Tier 3 — Speculative: Plausible but unverified by mainstream science.
• Tier 4 — Dubious: No credible support or contradicted by evidence.
• This project maps multiple perspectives — not a single truth. Mainstream,

alternative, and skeptical viewpoints are presented side by side for

critical comparison, not endorsement. Inclusion does not imply agreement.

• We are actively improving. Source verification, factuality scoring,

and bibliography enrichment are ongoing. Each revision adds stronger

citations, corrects identified errors, and expands coverage.

📖 For full details on our verification methodology, scoring systems, and

quality metrics, see: Fact-Checking & Verification Systems

Think Openly. Check the sources. Draw your own conclusions.

</td></tr>

</table>